Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2022.12675 MMR-25-05-12675 Articles Potential impact of GCK, MIR-196A-2 and MIR-423 gene abnormalities on the development and progression of type 2 diabetes mellitus in Asir and Tabuk regions of Saudi Arabia MirMohammad Muzaffar 1 MirRashid 2 AlghamdiMushabab Ayed Abdullah 3 WaniJaved Iqbal 4 ElfakiImadeldin 5 SabahZia Ul 4 AlhujailyMuhanad 6 JeelaniMohammed 1 MarakalaVijaya 1 AlharthiMuffarah Hamid 7 Al-ShahraniAbdullah M. 7 Department of Basic Medical Sciences, College of Medicine, University of Bisha, Bisha 61922, Kingdom of Saudi Arabia Prince Fahd Bin Sultan Research Chair, Department of Medical Laboratory Technology (MLT), Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia Department of Internal Medicine, College of Medicine, University of Bisha, Bisha 61922, Kingdom of Saudi Arabia Department of Internal Medicine College of Medicine, King Khalid University, Abha 61421, Kingdom of Saudi Arabia Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha 61922, Kingdom of Saudi Arabia Department of Family Medicine, College of Medicine, University of Bisha, Bisha 61922, Kingdom of Saudi Arabia Correspondence to: Professor Mohammad Muzaffar Mir, Department of Basic Medical Sciences, College of Medicine, University of Bisha, 8989 King Saud Road, Bisha 61922, Kingdom of Saudi Arabia, E-mail: mmmir@ub.edu.sa Dr Rashid Mir, Prince Fahd Bin Sultan Research Chair, Department of Medical Laboratory Technology (MLT), Faculty of Applied Medical Sciences, University of Tabuk, G232 Duba Road, Tabuk 71491, Kingdom of Saudi Arabia, E-mail: rashid@ut.edu.sa 05 2022 14 03 2022 25 5 162 13012022 28022022 Copyright: © Mir et al. 2022 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by persistent hyperglycemia and is associated with serious complications. The risk factors for T2DM include both genetic and lifestyle factors. Genome-wide association studies have indicated the association of genetic variations with many diseases, including T2DM. Glucokinase (GCK) plays a key role in the regulation of insulin release in the pancreas and catalyzes the first step in glycolysis in the liver. Genetic alterations in the GCK gene have been implicated in both hyperglycemia and hypoglycemia. MicroRNAs (miRNAs/miRs) are small non-coding RNA molecules that are involved in the important physiological processes including glucose metabolism. In the present study, the association of the single nucleotide polymorphisms (SNPs) in the GCK, MIR-196A-2 and MIR-423 genes with susceptibility to T2DM in patients from two regions of Saudi Arabia were examined, using the tetra-primer amplification refractory mutation system. The results showed that the AA genotype and the A allele of GCK rs1799884 were associated with T2DM [odds ratio (OR)=2.25, P=0.032 and OR=1.55, P=0.021, respectively]. Likewise, the CT genotype and T allele of MIR-196A-2 rs11614913 were associated with an increased risk of T2DM (OR=2.36, P=0.0059 and OR=1.74, P=0.023, respectively). In addition, the CA genotype of MIR-423 rs6505162 C>A was found to be linked with T2DM (OR=2.12 and P=0.021). It was concluded in the present research study that gene variations in GCK, MIR-196A-2 and MIR-423 are potentially associated with an increased risk of T2DM. These results, in the future, may help in the identification and stratification of individuals susceptible to T2DM. Future longitudinal studies with larger sample sizes and in different ethnic populations are recommended to validate these findings.

 glucokinase rs1799884 MIR-196A-2 (rs11614913) MIR-423 (rs6505162) single nucleotide polymorphism type 2 diabetes mellitus Saudi Arabia tetra-primer amplification refractory mutation system-polymerase chain reaction Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia The authors extend their appreciation to the ‘Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number 47 of 1442. Introduction

Diabetes mellitus (DM) is one of the major health issues worldwide and the Kingdom of Saudi Arabia (KSA) has a high prevalence of DM (1,2). In general, there are two types of DM: type 1 DM (T1DM) is caused by the destruction of pancreatic β cells that secrete insulin (3) and type 2 DM (T2DM) which develops by tissue resistance to insulin action and pancreatic β cell dysfunction (3). DM is associated with acute consequences including diabetic ketoacidosis, hyperosmolar hyperglycemic syndrome and chronic complications such as renal failure, blindness, cardiovascular disease and diabetic neuropathy (4). These complications unfortunately result in high rates of morbidity and mortality. Both T1DM and T2DM are heterogenous and polygenic in nature with distinct characteristics (2,5).

Glucokinase (GCK) or hexokinase IV (EC 2.7.1.2) catalyzes the conversion of glucose to glucose-6-phosphate (step 1 in glycolysis) in the liver and pancreas; and in other cells, this reaction is catalyzed by hexokinase I (6). In hepatocytes, GCK enhances glucose uptake for glycogenesis and energy storage, whereas in the pancreas, GCK senses elevated blood sugar and stimulates the insulin release by pancreatic β cells (6,7). GCK activators enhance the pancreatic secretion of insulin and hence increase hepatic glycogenesis (7,8). The elevated liver glucose output is the main hepatic dysfunction associated with T2DM (8). Genetic variants of the GCK gene have been implicated in gestational diabetes mellitus (GDM) (9–11), neonatal diabetes (12) and T2DM (13–15). GCK SNP rs4607517 T > C has been reported to cause T2DM in American Indians (16), and rs1799884 G > A has been associated with T2DM in Dutch (17), French (18) and Moroccan (19) populations.

MicroRNAs (miRNAs/miRs), small non-coding RNA molecules, regulate gene expression and are involved in important physiologic processes (20). miRNA dysfunctions have been implicated in several diseases, such as cancer, cardiovascular disease and diabetes (21–26). It has been reported that MIR-196A-2 is involved in the regulation of insulin signaling pathways (27) and that gene variation in MIR-196A-2 can induce T2DM through the regulation of body fat distribution (28). The miR-423 blood levels are significantly decreased in cases with proliferative diabetic retinopathy (29). The inhibition of miR-423-5p decreases gluconeogenesis, reduces insulin resistance and decreases blood glucose (13). In contrast, overexpression of liver miR-423-5p increases gluconeogenesis, elevates blood glucose, and enhances the deposition of fat in mice (30).

In the present study, GCK, MIR-196A-2 and MIR-423 genotyping was conducted using Tetra primer-amplification refractory mutation system-based polymerase chain reaction (T-ARMS-PCR) to evaluate the potential clinical association of GCK rs1799884 G>A, MIR-196A-2 rs11614913 C>T and MIR-423 rs6505162 C>A with the development and progression of T2DM in individuals in the Asir and Tabuk regions of Saudi Arabia. This technique is based on the use of sequence-specific PCR primers that allow amplification of test DNA only when the target allele is contained within the sample. It involves a single PCR followed by gel electrophoresis. Designing primers for the mutant [with single nucleotide polymorphisms (SNPs)] and normal (without SNP) alleles allows selective amplification which can be easily analyzed after electrophoresis. It utilizes four primers viz forward outer (FO), reverse outer (RO), forward inner (FI) and reverse inner (RI) primers. The FO/RO primer combination generates the outer fragment of the SNP locus and acts as an internal control for the PCR. The FI/RO and FO/RI primer combinations yield allele-specific amplicons depending on the genotype of the sample used. The inner primers are positioned unequally from the corresponding outer primer to generate amplicons with different sizes and hence easily resolvable in a gel and distinction is made accordingly. T-ARMS PCR is a flexible, rapid and economical SNP detection tool compared to contemporary genotyping tools such as allele-specific PCR (31).

 Materials and methods <sec> <title>Study population

This population-based case-control, collaborative study was conducted on 110 T2DM patients and 110 healthy controls. Specimens were collected from Asir and Tabuk regions of Saudi Arabia in the following hospitals: Bisha: Diabetic Center, King Abdullah Hospital, Bisha; Abha: Asir General Hospital, Abha; Tabuk: King Fahd Specialty Hospital, Tabuk. The recruitment period of the patients and controls was from March 2021 to October, 2021. Informed consent was obtained prior to the collection of samples from all patients and control subjects.

 Ethical approval

Ethical approval was obtained from the local RELOC Committee of the College of Medicine, University of Bisha (ref. no. UBCOM/H-06-BH-087(04/10), in accordance with the local guidelines which conformed in essence, to the principles of the Helsinki Declaration.

 Inclusion criteria

All the study subjects were citizens of Saudi Arabia and included clinically confirmed cases with T2DM (both males and females). The selected patients included those with fasting plasma glucose levels >110 mg/dl and/or those clinically confirmed patients who were on oral hypoglycemic agents or insulin and had fasting glucose levels <110 mg/dl on the day of blood sampling. Patients with random blood glucose >200 mg/dl and/or those clinically confirmed patients who were on oral hypoglycemic agents or insulin and had random glucose levels <200 mg/dl on the day of blood sampling were also included.

 Exclusion criteria

The T2DM patients with other significant chronic diseases, such as renal failure, liver cirrhosis and malignancies were excluded from the study. Type 1 diabetes patients were also excluded from the study.

 Inclusion criteria for controls

The control subjects were healthy volunteers with no history of diabetes or any major clinical disorders (including dyslipidemia) and had normal fasting and random plasma glucose levels.

 Data collection

This study included clinically confirmed cases of T2DM in Saudi Arabia who visited the hospitals in Abha, Bisha and Tabuk regions. This case-control study enrolled 110 subjects with T2DM and 110 normal control subjects for each SNP. T2DM was diagnosed according to the parameters of WHO criteria (who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf). The various variables that were analyzed from the T2DM patients and controls included the case history, age and sex, duration of T2DM (only for patients), glycated hemoglobin (HbA1c), fasting and random blood glucose levels, total cholesterol, triacylglycerol (TG), high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) concentrations, total cholesterol/HDL-C ratios and serum creatinine. The biochemical parameters were assayed using standard protocols.

 Sample collection from the T2DM patients

Approximately 3 ml of peripheral blood sample was collected in an EDTA or Lavender top tube for all T2DM patients. One aliquot of the blood specimens was immediately stored at −20 to −30°C until further molecular studies. Another aliquot of blood (~2 ml) was collected in a red top tube and immediately sent for biochemical analyses.

 Sample collection from healthy controls

All healthy age-matched control specimens were timed around routine blood draws that were part of the routine workout and hence did not require additional phlebotomy. All participants provided a written informed consent form. Approximately 3 ml peripheral blood was collected in EDTA tubes. The blood specimens for molecular studies were immediately stored at −20 to −30°C until further analyses. Another aliquot of blood (~2 ml) was collected in a red top tube and immediately sent for biochemical analyses.

 Genomic DNA extraction

Genomic DNA was extracted using DNeasy Blood K (Qiagen GmbH) as per the manufacturer's instructions. The extracted DNA was dissolved in nuclease-free water and stored at 4°C until use. The quality and integrity of the DNA were checked by NanoDrop™ (Thermo Fisher Scientific, Inc.). All DNA samples from the patients and controls were screened for purity by measuring optical density (OD) at 260 nm (OD260) and 280 nm (OD280). The λ260/λ280 ratios ranged from 1.83-1.99 indicating good quality DNA.

 Genotyping of GCK, MIR-19A-2 and MIR-423 genes by T-ARMS-PCR

The primers for GCK rs1799884 G>A and MIR-196A-2 rs11614913 C>T were designed by using primer3 software (version 0.4.0, Whitehead Institute of Biomedical Research). T-ARMS-PCR primers were optimized by gradient PCR. The ARMS-PCR primers for MIR-423 rs6505162 C>A were prepared by following previously used standard procedures (32,33). Reference sequence rs1799884 was used to design the primers for GCK. For MIR-196A-2 rs11614913 C>T and MIR-423 rs6505162 C>T ARMS primers were designed according to previously used procedures (32,33). The primers for all three SNPs are depicted in Table I.

 Preparation of the PCR cocktail

T-ARMS-PCR was performed in a reaction volume of 25 µl containing template DNA (50 ng), 0.25 µl primer stock solution FO, RO, FI and RI, containing 5 pmol of each primer and 10 µl from GoTaq® Green Master Mix (cat no M7122; Promega Corp.). The final volume of 25 µl was adjusted by adding nuclease-free ddH2O. Finally, 2 µl of DNA was added from each subject.

 Thermocycling conditions

The thermocycling conditions used were at 95°C for 10 min followed by 40 cycles of 95°C for 35 sec, annealing temperature GCK rs1799884 G→A (59ºC), MIR-196A-2 rs11614913 C>T (61ºC) and MIR-423 rs6505162 C>A genes (62ºC), extension for 72°C for 45 msec and final extension at 72°C for 10 min.

 Gel electrophoresis for GCK amplification

GCK rs1799884 G>A PCR products were separated on 2% agarose gel stained with 2 µl of SYBR Safe stain (Thermo Fisher Scientific, Inc.) and visualized on a UV transilluminator (Bio-Rad Laboratories, Inc.). Primers FO and RO flank the exon of the GCK rs1799884 G>A gene, resulting in a band of 390 bp to act as a control for DNA quality and quantity. Primers FO and RO amplify a wild-type allele (G allele), generating a band of 181 bp, and primers FO and reverse mutant) generate a band of 252 bp from the mutant allele (A allele). The results are depicted in Fig. 1.

 Gel electrophoresis for MIR-196A-2 amplification

The amplification products for MIR-196A-2 rs11614913 C>T amplification were separated by electrophoresis through 2% agarose gel stained with 0.5 µg/ml ethidium bromide and visualized on a UV transilluminator. Primers FO and RO flank the exon of the MIR-196A-2 rs11614913 C>T gene, resulting in a band of 297 bp to act as a control for DNA quality and quantity. Primers FO and RO amplify a wild-type allele (C allele), generating a band of 153 bp, and primers FO and RI generate a band of 199 bp from the mutant allele (T allele). The electrophoresis gel image is shown in Fig. 2.

 Gel electrophoresis for MIR-423 amplification

PCR products were separated on 2% agarose gel stained with 2 µl of SYBR Safe stain and visualized on a UV transilluminator. Primers FO and RO flank the exon of the MIR-423 rs6505162 C>T gene, resulting in a band of 336 bp to act as a control for DNA quality and quantity. Primers FO and RO amplify a wild-type allele (C allele), generating a band of 160 bp, and primers FO and RO generate a band of 228 bp from the mutant allele (T allele).

 Statistical analysis

Group differences were compared using the Student's two-sample t-test or one-way analysis of variance (ANOVA) for continuous variables and the Chi-squared test for categorical variables. Differences in the GCK rs1799884 G>A, MIR-196A-2 rs11614913 C>T and MIR-423 rs6505162 C>A allele and genotype frequencies between groups were evaluated using the Chi-square test. The associations between GCK, MIR-196A-2 and MIR-423 genotypes with the risk of T2DM were estimated by computing the odds ratios (ORs), risk ratios (RRs) and risk differences (RDs) with 95% confidence intervals (CIs). OR was calculated by dividing the odds of the first group by the odds in the second group. The interpretation of the OR depends on whether the predictor is categorical or continuous. ORs that are >1 indicate that the event is more likely to occur as the predictor increases. Odds ratios that are <1 indicate that the event is less likely to occur as the predictor increases. OR >1.0 indicates that the odds of exposure among patients are greater than the odds of exposure among controls. For example, an OR of 1.2 is above 1.0, but is not a strong association while as an OR of 10 suggests a stronger association. Deviation from Hardy-Weinberg disequilibrium (HWD) was calculated by Chi-square (χ2) ‘goodness of fit test’. Allele frequencies among patients and controls were evaluated by using the Chi-square Hardy-Weinberg equilibrium test. A P-value <0.05 was considered as indicative of a statistically significant difference. The univariate and multivariate analyses were calculated by using MedCalc software, version 20.027 (medcalc.org/calc/odds_ratio.php)/SPSS 16.0 (SPSS, Inc.).

 Results <sec> <title>Demographic features and baseline characteristics

The demographic features and the baseline characteristics of the 110 consecutive T2DM patients are summarized in Table II. Of the 110 consecutive patients, 61 were males and 49 were females, 20 patients were ≤40 years of age and 23 were >40 years of age. The age range of the patients was 24–77 years with a mean of 50.32 years. The age range of the control group was 26–77 years with a mean age of 51.46 years. Among the 110 T2DM patients, 28 had fasting glucose ≤110 mg/dl and 82 had glucose >110 mg/dl. Random blood glucose (RBG) was ≤200 mg/dl in 56 and >200 mg/dl in 54 patients respectively. A total of 60 T2DM patients had total cholesterol ≤200 mg/dl and 50 had total cholesterol >200 mg/dl. Among the 110 T2DM patients, 64 had triglycerides (TG) >150 mg/dl and 46 had triglycerides ≤150 mg/dl. The HDL-cholesterol was ≤55 mg/dl in 82 while it was >55 mg/dl in 28 patients, respectively. The LDL-cholesterol was ≤100 mg/dl in 30 while it was >100 mg/dl in 75 patients, respectively. Differences in the mean of the serum lipid profile for HDL-C, LDL-C, total cholesterol and TG were significant between the patient and controls (P=0.0001). A total of 80 T2DM patients had HbA1c >6% and 30 had HbA1c ≤6%. The serum creatinine values were ≤1.35 mg/dl in 83 and >1.35 in 27 patients, respectively.

 Statistical comparisons of GCK (rs1799884 G>A) genotypes in the T2DM patients and controls

At the time of analysis, all of the 110 T2DM patients displayed results in gel electrophoresis whereas only 107 healthy controls displayed sharp bands in the gel. As such only 107 results were included for the analyses. The results indicated that there were significant differences in genotype distribution of the GCK rs1799884 G>A genotypes between T2DM patients and controls (P<0.015) (Table III). The frequency of the genotypes (GG, GA and AA) between the patients and controls was 23.7% 39 and 37.3 and 28, 52.3 and 19.7%, respectively. A higher frequency of the A allele (0.57) was reported in T2DM patients in comparison to the healthy controls (0.46).

 Multivariate analysis to estimate the association between GCK genotypes and risk to T2DM

The presented study, significantly, yielded the following results. a) The AA genotype was associated with T2DM with OR=2.25 (1.071 to 4.737), RR=1.58 (1.034 to 2.418), P<0.0320 (Table IV). b) The A allele of the rs1799884 G>A was associated with T2DM with an OR=1.55 (1.066 to 2.274), 1.25 (1.032 to 1.515), P<0.0210 (Table IV). (c) There was a significant difference (P<0.05) in genotype distribution of rs1799884 G>A between males and females (Table V). d) There were significant differences in rs1799884 G>A genotype distribution between patients with normal and elevated fasting and random glucose and HbA1c (P<0.05) (Table V). e) Finally, there were significant differences in the rs1799884 G>A genotype distribution between patients with normal and abnormal lipid profiles (Table V).

 Association of MIR-196A-2 rs11614913 C>T genotypes with T2DM

At the time of analysis, out of 110, only 100 T2DM patient samples gave sharp bands in gel electrophoresis for MIR-196A-2 rs11614913 C>T genotyping. Similarly, for controls only 100 displayed sharp bands. The results in this analysis indicated there was a significant difference (P<0.0190) in the MIR-196A-2 rs11614913 C>T genotype between patients and controls (Table VI).

 Multivariate analysis to estimate the association between MIR-196A-2 rs11614913 C>T genotypes and T2DM risk

Results showed that MIR-196A-2 rs11614913 CT genotype was associated with T2DM with OR=2.36 (1.2816 to 4.348), RR=1.57 (1.1124 to 2.225), P=0.0059 (Table VII). The T allele of the MIR-196A-2 rs11614913 was associated with T2DM with OR=1.74 (1.0787 to 2.807), RR=1.35 (1.0217 to 1.787), P=0.023 (Table VII).

 Statistical correlation of MIR-196A-2 rs11614913 C>T genotypes with patient characteristics

The results indicated that there were significant differences in the MIR-196A-2 rs11614913 genotype distribution between patients with normal and those with elevated random blood glucose (RBG) and HbA1c (P=0.0050 and =0.0380, respectively) (Table VIII).

 Association of MIR-423 rs6505162 C>A gene variation with T2DM

At the time of analysis, out of 110, only 100 T2DM patient samples gave sharp bands in gel electrophoresis. Similarly, for the controls only 100 displayed sharp bands. As such only 107 results were included for the analyses. The results indicated that there was a significant difference in genotype distribution of the MIR-423 rs6505162 C>A genotypes between T2DM patients and controls (P<0.0240) (Table IX). The frequency of CC, CA and AA genotypes was 23, 67 and 10% for patients, and 35, 48 and 17% for the controls, respectively. A higher frequency of C allele (0.62) was reported in T2DM patients than among the healthy controls (0.59 (Table IX).

 Multivariate analysis to estimate the association between MIR-423 rs6505162 C>A gene genotypes and risk to T2DM

The results showed that the CA genotype was associated with T2DM with OR=2.12 (1.1160 to 4.0426), RR=1.44 (1.0708 to 1.952), P<0.0210 in the codominant model (Table X). The results also indicated that there were no significant differences in the MIR-423 rs6505162 C>A genotypes in dominant, recessive and over-dominant alleles (Table X).

 Association of MIR-423 rs6505162 C>A with T2DM patient characteristics

The statistical comparisons (P-values) of MIR-423 rs6505162 C>A genotypes with comorbid conditions and T2DM severity was conducted by using multivariate analysis based on logistic regression such as odds ratio (OD) and risk ratio (RR) with 95% confidence intervals (CI) (Table XI). A significant correlation was reported between the MIR-423 rs6505162 C>A genotypes and the age of the subjects (P<0.0001). A significant correlation was reported between the MIR-423 rs6505162 C>A genotypes with biochemical parameters such as fasting glucose, RBG, total serum cholesterol, LDL-C, TG and HbA1c.

 Discussion

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia resulting from impaired insulin action caused by insulin resistance in the liver, muscles and adipose tissues (3,34). Insulin resistance leads to hyperinsulinemia and pancreatic β cell dysfunction (34). Glucokinase is very important for glucose homeostasis, since it is essential for insulin secretion, energy storage as glycogen, and gluconeogenesis (35). The rs1799884 SNP is found in the specific promoter region of the glucokinase (GCK) gene (14). The results revealed that there was a significant difference in rs1799884 G>A genotype distribution between the T2DM patients and the controls. The A allele of the rs1799884 G>A was also associated with T2DM (Table V). This result is consistent with previous studies that indicated the association of rs1799884 with an increased fasting blood glucose concentration and susceptibility to T2DM (13–16). Simultaneously, the result is also in agreement with previous studies as well which reported that i) rs1799884 influences glucokinase activity and that the reduced glucokinase activity is associated with T2DM (14,36–39), and ii) rs1799884 SNP is associated with dyslipidemia and coronary artery disease (CAD) in Han Chinese and Austrian populations (40,41).

The present results also revealed that rs1799884 GA and AA genotypes were associated with hyperlipidemia. Hyperlipidemia and cardiovascular diseases are among the traditional complications of diabetes mellitus (38–40). This result is substantiated by a recent study by Ormazabal et al, who reported that the systemic metabolism of lipids is altered in the insulin resistance that leads to the so-called lipid triad; hypertriglyceridemia, reduced HDL and the development of small dense LDL (41). In the stratified analysis by ethnicity, significant associations have been found in Caucasians for the polymorphism in all genetic models; while no associations were detected among Asians (13,19). There are several possible reasons for such differences. First, the distribution of the A allele varies extensively between different races, ethnicities, with a prevalence of ~23% among Asians and ~17% among Caucasians. The frequency of three genotypes GG, GA, AA between the T2DM patients and controls was found to be 23, 39 and 37.3% and 28, 52.3 and 19.7% respectively. A higher frequency of A allele (0.57) was reported in our T2DM cases when compared with the healthy controls (0.46). Therefore, additional studies are warranted to further validate the ethnic difference in the effect of this polymorphism on T2DM risk.

The results on MIRNA SNPs showed that the CT genotype and the T allele of MIR-196A-2 rs11614913 were associated with T2DM. This result is in agreement with a recent study that reported MIR-196A-2 rs11614913 to be associated with T2DM in a Pakistani population (42). The MIR-196A-2 rs11614913 C>T SNP has been reported to influence the expression of mature mRNAs by binding with target mRNAs (25,43), and the T allele is associated with reduced mature miR-196a-2 levels (44). It has been reported that miR-196a-2 directly targets and inhibits the expression of Scm like with four Mbt domains 1 (SFMBT1) and homeobox C8 (HOXC8) genes (43,44). The HOXC8 gene was reported to increase white fat cells and the susceptibility to obesity (44), while SFMBT1 was demonstrated to be among the adiponectin level-regulating loci (45). The blood levels of adiponectin are genetically determined and correlate negatively with the susceptibility to T2DM and cardiovascular diseases (45). It has also been suggested that a reduction in the mature miR-196a-2 by rs11614913 T allele increases the expression of HOXC8 and SFMBT1 leading to obesity probably by the promotion of white fat cells (44). Obesity is a well-established risk factor for insulin resistance and the development of T2DM (46). The results indicated that there were significant differences (P<0.05) in MIR-196A-2 rs11614913 C>T SNP genotype distribution between the subjects with normal and abnormal lipid profiles.

Human miR-196 (miR-196a-1, miR-196a-2, and miR-196b) is transcribed from three different genes located on chromosomes 17q21, 12q13, and 7p15, respectively. The nucleotide sequences of miR-196a-1 and miR-196a-2 are identical, while the sequence of miR-196b differs from that of miR-196a by only one nucleotide in the non-seed region. Previous research has shown that the expression level of mature miR-196a-3p is higher in CC carriers with lung cancer compared to CT and TT individuals (47). Hoffman et al reported elevated expression of mature miR-196a-2 forms in MCF-7 cells transfected with a pre-miR-196a-C vector when compared with cells transfected with a pre-miR-196a-T vector (43). The potential of rs11614913 in targeting the function of miR-196a-2 has also been documented by whole-genome expression microarrays which found different numbers of dysregulated mRNAs after transfecting cells with a pre-miR-196a-C or pre-miR-196a-T vector (43). It is plausible to believe that rs11614913 C®T SNP may affect the binding efficiency of miR-196a-2 to its target mRNA or it might affect the processing of the pre-miRNA into its mature form, thereby predisposing the individuals to T2DM (48).

It was observed that the cases with a CT genotype had low serum cholesterol and TG values. Since this is a cross sectional study, it is possible that these cases have received cholesterol-lowering medications and their normal lipid profiles were already maintained prior to the sample collection.

This result is rather expected as the MIR-196A-2 rs11614913 C>T SNP has been associated with cardiovascular disease (CVD) in previous studies in different populations (49–52). miR-196a-2 is involved in the regulation of annexin A1 known for reducing the levels of tumor necrosis factor-α (TNF-α) (53). TNF-α has an important role in the induction of CVD (53). Moreover, it has been reported that miR-196a-2 regulates HOXB8-Shh signaling in fetal cardiac tissues that is required for cardiac septation, morphogenesis and valve development. Therefore, dysregulation of miR-196a-2 may lead to CVD (54,55). The results of this study are substantiated by a similar study that reports that the CC genotype of MIR-196A-2 rs11614913 affects the maturation of miR-196a-2 and its interaction with its target mRNAs (55,56).

The rs6505162 C>A is located in the pre-miRNA sequence of MIR-423 that expresses two microRNAs, MIR-423-3P and MIR-423-5P (52). The current results showed that there was a significant difference in MIR-423 rs6505162 C>A genotype distribution between T2DM patients and controls, and that the CA genotype of the MIR-423 rs6505162 C>A was associated with T2DM. The A allele of rs6505162 has been reported to increase the expression of the mature miR-423 (53,54). The result of this study is quite consistent with the study by Yang et al who reported that in obese diabetic mice suppression of liver miR-423-5p inhibits gluconeogenesis and ameliorates insulin resistance, and promotes blood sugar and fatty liver (30). They further reported that the overexpression of miR-423-5p enhanced gluconeogenesis, increased blood glucose levels and obesity in healthy mice through the suppression of the hepatic FAM3A/ATP/Akt pathway (30). However, the result is in disagreement with a study that reported no association of rs6505162 with the induction of T2DM in the Pakistani population (42). This dissimilarity of findings is probably due to different subject ethnicity and sample size and requires further validation. The present results showed that there were significant differences in rs6505162 genotype distribution in cases with normal and abnormal lipid profiles. This result is rather expected as the rs6505162 SNP has been associated with cardiovascular disease (57,58). The result of this study is also consistent with studies that demonstrated that the overexpression of miR-423-5p enhanced fat deposition and that miR-423-5p is specifically increased in the blood of heart failure subjects (30,58).

In the present study Tetra primer-amplification refractory mutation system-based polymerase chain reaction (T-ARMS-PCR) was successfully used, although the genotyping methods including high-resolution melting (HRM), pyrosequencing, TaqMan assay, Mass ARRAY are highly accurate and acknowledged as gold standard for detecting SNPs but require expensive equipment and kits. The other alternative methods that could have been used include quantitative PCR, PCR-RFLP and direct sequencing but T-ARMS-PCR has been reported to be cost-effective, reliable and simple (31). The results of T-ARMS-PCR have been reported to be consistent with DNA sequencing results by Jin et al (58) that reiterates our belief that T-ARMS-PCR can offer a viable, simple and reliable alternative for the detection of SNPs.

To conclude, the SNPs of GCK rs1799884 G>A, MIR-196A-2 rs11614913 C>T, MIR-423 rs6505162 were examined for their association with T2DM in a section of the Saudi population by using T-ARMS-PCR. The results indicated that the AA genotype and the A allele of the GCK rs1799884 G>A were strongly associated with T2DM susceptibility in the patient population. The results also indicated that the MIR-196A-2 rs11614913 CT genotype and T allele and MIR-423 rs6505162 CA genotype were also associated with T2DM. Since this is the first study of its kind in Saudi Arabia, the results will help in uncovering more loci that are associated with T2DM in different ethnic populations and the stratification of individual susceptible to T2DM. The limitations of this study include the small sample size and no strict age matching between patients and healthy controls. More longitudinal studies with larger sample sizes and in different ethnic populations are recommended to further validate these observations.

 Acknowledgements

The authors extend their appreciation to Dr. Suhail Ahmed of the English Department, University of Bisha, for language review and editing.

 Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

 Authors' contributions

All the authors were involved in the conception and planning of the study. MMM, RM, MAAA, MJ, VM and MHA designed the study. MAAA, JIW, ZUS, MA and AMA were involved in the recruitment of patients. MMM, RM, MJ and IE performed the experiments. RM and MMM confirm the authenticity of all the raw data. MMM, RM and IE wrote the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Ethical approval was obtained from the local RELOC Committee of the College of Medicine, University of Bisha (ref. no. UBCOM/H-06-BH-087(04/10), in accordance with the local guidelines which conformed in essence, to the principles of the Helsinki Declaration. Informed consent was obtained prior to the collection of samples from all patients and control subjects.

 Patient consent for publication

Not applicable.

 Competing interests

The authors state that they have no competing interests.

 References Al MansourMAThe prevalence and risk factors of type 2 diabetes mellitus (DMT2) in a semi-urban Saudi populationInt J Environ Res Public Health177201910.3390/ijerph1701000731861311 GaálZBaloghIMonogenic forms of diabetes mellitusExp Suppl111385416201931588541 MoinASMButlerAEAlterations in beta cell identity in type 1 and type 2 diabetesCurr Diab Rep1983201910.1007/s11892-019-1194-631401713 ForbesJMCooperMEMechanisms of diabetic complicationsPhysiol Rev93137188201310.1152/physrev.00045.201123303908 SacksDBMcDonaldJMThe pathogenesis of type II diabetes mellitus. A polygenic diseaseAm J Clin Pathol105149156199610.1093/ajcp/105.2.1498607437 De BackerIHussainSSBloomSRGardinerJVInsights into the role of neuronal glucokinaseAm J Physiol Endocrinol Metab311E42E55201610.1152/ajpendo.00034.201627189932 IynedjianPBMolecular physiology of mammalian glucokinaseCell Mol Life Sci662742200910.1007/s00018-008-8322-918726182 ToulisKANirantharakumarKPourzitakiCBarnettAHTahraniAAGlucokinase activators for type 2 diabetes: Challenges and future developmentsDrugs80467475202010.1007/s40265-020-01278-z32162273 OsbakKKColcloughKSaint-MartinCBeerNLBellanné-ChantelotCEllardSGloynALUpdate on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemiaHum Mutat3015121526200910.1002/humu.2111019790256 FendLerWRizzoMBorowiecMMalachowskaBAntosikKSzadkowskaABanachMUrbanska-KosinskaMSzopaMMaleckiMMlynarskiWLess but better: Cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol levelActa Diabetol51625632201410.1007/s00592-014-0567-124549415 SpyerGMacleodKMShepherdMEllardSHattersleyATPregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutationDiabet Med261418200910.1111/j.1464-5491.2008.02622.x19125755 NjølstadPRSøvikOCuesta-MuñozABjørkhaugLMassaOBarbettiFUndlienDEShiotaCMagnusonMAMolvenANeonatal diabetes mellitus due to complete glucokinase deficiencyN Engl J Med34415881592200110.1056/NEJM20010524344210411372010 FuDCongXMaYCaiHCaiMLiDLvMYuanXHuangYLvZGenetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: Evidence based on 298,468 subjectsPLoS One8e55727201310.1371/journal.pone.005572723441155 MuradASSmithGDLewisSJCoxADonovanJLNealDEHamdyFCMartinRMA polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: Findings from a population-based, case-control study (the ProtecT study)Int J Mol Epidemiol Genet1175183201021537389 LiCYangYLiuXLiZLiuHTanQGlucose metabolism-related gene polymorphisms as the risk predictors of type 2 diabetesDiabetol Metab Syndr1297202010.1186/s13098-020-00604-533292424 MullerYLPiaggiPHoffmanDHuangKGeneBKobesSThearleMSKnowlerWCHansonRLBaierLJBogardusCCommon genetic variation in the glucokinase gene (GCK) is associated with type 2 diabetes and rates of carbohydrate oxidation and energy expenditureDiabetologia5713821390201410.1007/s00125-014-3234-824728127 ReilingEvan 't RietEGroenewoudMJWelschenLMvan HoveECNijpelsGMaassenJADekkerJM't HartLMCombined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes riskDiabetologia5218661870200910.1007/s00125-009-1413-919533084 CauchiSNeadKTChoquetHHorberFPotocznaNBalkauBMarreMCharpentierGFroguelPMeyreDThe genetic susceptibility to type 2 diabetes may be modulated by obesity status: Implications for association studiesBMC Med Genet945200810.1186/1471-2350-9-4518498634 CauchiSEzzidiIEl AchhabYMtiraouiNChaiebLSalahDNejjariCLabruneYYengoLBeuryDEuropean genetic variants associated with type 2 diabetes in North African ArabsDiabetes Metab38316323201210.1016/j.diabet.2012.02.00322463974 CirilloFCatellaniCLazzeroniPSartoriCStreetMEThe role of MicroRNAs in influencing body growth and developmentHorm Res Paediatr93715202010.1159/00050466931914447 TanWLiuBQuSLiangGLuoWGongCMicroRNAs and cancer: Key paradigms in molecular therapyOncol Lett1527352742201829434998 RaueRFrankACSyedSNBrüneBTherapeutic targeting of MicroRNAs in the tumor microenvironmentInt J Mol Sci222210202110.3390/ijms2204221033672261 FridrichovaIZmetakovaIMicroRNAs contribute to breast cancer invasivenessCells81361201910.3390/cells811136131683635 AshrafizadehMAngHLMoghadamERMohammadiSZarrinVHushmandiKSamarghandianSZarrabiANajafiMMohammadinejadRKumarAPMicroRNAs and their influence on the ZEB family: Mechanistic aspects and therapeutic applications in cancer therapyBiomolecules101040202010.3390/biom1007104032664703 MirRElfakiIKhullarNWazaAAJhaCMirMMNisaSMohammadBMirTAMaqboolMRole of selected miRNAs as diagnostic and prognostic biomarkers in cardiovascular diseases, including coronary artery disease, myocardial infarction and atherosclerosisJ Cardiovasc Dev Dis822202110.3390/jcdd802002233669699 ElfakiIMirRDuhierFMAAlotaibiMAAlalawyAIBarnawiJBabakrATMirMMAltayebFMirghaniHFrahEAMClinical implications of MiR128, angiotensin I converting enzyme and vascular endothelial growth factor gene abnormalities and their association with T2DCurr Issues Mol Biol4318591875202110.3390/cimb4303013034889890 IbrahimAARamadanAWahbyAAHassanMSolimanHMAbdel HamidTAMicro-RNA 196a2 expression and miR-196a2 (rs11614913) polymorphism in T1DM: A pilot studyJ Pediatr Endocrinol Metab3211711179201910.1515/jpem-2019-022631472066 ZhuangGQWangYXA tiny RNA molecule with a big impact on type 2 diabetes mellitus susceptibilityBiomed Environ Sci30855861201729216965 BlumAMeersonARohanaHJabalyHNahulNCeleshDRomanenkoOTamirSMicroRNA-423 may regulate diabetic vasculopathyClin Exp Med19469477201910.1007/s10238-019-00573-831422516 YangWWangJChenZChenJMengYChenLChangYGengBSunLDouLNFE2 induces miR-423-5p to promote gluconeogenesis and hyperglycemia by repressing the hepatic FAM3A-ATP-Akt pathwayDiabetes6618191832201710.2337/db16-117228411267 DelvauxNda CostaVDda CostaMMLampeEComparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patientsJ Virol Methods22014201510.1016/j.jviromet.2015.04.00125863261 JhaCKMirRElfakiIKhullarNRehmanSJavidJBanuSChahalSMSPotential impact of MicroRNA-423 gene variability in coronary artery diseaseEndocr Metab Immune Disord Drug Targets196774201910.2174/187153031866618100509572430289085 RahimAAfzalMNaveedAKGenetic polymorphism of miRNA-196a and its target gene annexin-A1 expression based on ethnicity in Pakistani female breast cancer patientsPak J Med Sci3515981604201910.12669/pjms.35.6.132231777500 HudishLIReuschJESusselLβ Cell dysfunction during progression of metabolic syndrome to type 2 diabetesJ Clin Invest12940014008201910.1172/JCI12918831424428 MatschinskyFMWilsonDFThe central role of glucokinase in glucose homeostasis: A perspective 50 years after demonstrating the presence of the enzyme in islets of langerhansFront Physiol10148201910.3389/fphys.2019.0014830949058 TamCHHoJSWangYLeeHMLamVKGermerSMartinMSoWYMaRCChanJCNgMCCommon polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjectsPLoS One5e11428201010.1371/journal.pone.001142820628598 WeedonMNClarkVJQianYBen-ShlomoYTimpsonNEbrahimSLawlorDAPembreyMERingSWilkinTJA common haplotype of the glucokinase gene alters fasting glucose and birth weight: Association in six studies and population-genetics analysesAm J Hum Genet799911001200610.1086/50951717186458 TremblayJHametPBiomarkers of vascular complications in type 2 diabetesMetabolism64(3 Suppl 1)S28S32201510.1016/j.metabol.2014.10.03225468145 QiQWuYLiHLoosRJHuFBSunLLuLPanALiuCWuHAssociation of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese populationDiabetologia52834843200910.1007/s00125-009-1290-219241058 MärzWNauckMHoffmannMMNagelDBoehmBOKoenigWRothenbacherDWinkelmannBRG(−30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitusCirculation10928442849200410.1161/01.CIR.0000129306.44085.C415173029 OrmazabalVNairSElfekyOAguayoCSalomonCZuñigaFAAssociation between insulin resistance and the development of cardiovascular diseaseCardiovasc Diabetol17122201810.1186/s12933-018-0762-430170598 KhanMSRahmanBHaqTUJalilFKhanBMMaodaaSNAl-FarrajSAEl-SerehyHAShahAADeciphering the variants located in the MIR196A2, MIR146A, and MIR423 with type-2 diabetes mellitus in Pakistani populationGenes (Basel)12664202110.3390/genes1205066433925232 HoffmanAEZhengTYiCLeadererDWeidhaasJSlackFZhangYParanjapeTZhuYmicroRNA miR-196a-2 and breast cancer: A genetic and epigenetic association study and functional analysisCancer Res6959705977200910.1158/0008-5472.CAN-09-023619567675 GhanbariMSedaghatSde LooperHWHofmanAErkelandSJFrancoOHDehghanAThe association of common polymorphisms in miR-196a2 with waist to hip ratio and miR-1908 with serum lipid and glucoseObesity (Silver Spring)23495503201510.1002/oby.2097525557604 DastaniZHivertMFTimpsonNPerryJRBYuanXScottRAHennemanPHeidIMKizerJRLyytikäinenLPNovel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multi-ethnic meta-analysis of 45,891 individualsPLoS Genet8e1002607201210.1371/journal.pgen.100260722479202 WondmkunYTObesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implicationsDiabetes Metab Syndr Obes1336113616202010.2147/DMSO.S27589833116712 HuZChenJTianTZhouXGuHXuLZengYMiaoRJinGMaHGenetic variants of miRNA sequences and non-small cell lung cancer survivalJ Clin Invest11826002608200818521189 LiuCJTsaiMMHungPSKaoSYLiuTYWuKJChiouSHLinSCChangKWmiR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinomaCancer Res7016351644201010.1158/0008-5472.CAN-09-229120145132 FragosoJMRamírez-BelloJMartínez-RíosMAPeña-DuqueMAPosadas-SánchezRDelgadillo-RodríguezHJiménez-MoralesMPosadas-RomeroCVargas-AlarcónGmiR-196a2 (rs11614913) polymorphism is associated with coronary artery disease, but not with in-stent coronary restenosisInflamm Res68215221201910.1007/s00011-018-1206-z30560371 SungJHKimSHYangWIKimWJMoonJYKimIJChaDHChoSYKimJOKimKAmiRNA polymorphisms (miR-146a, miR-149, miR-196a2 and miR-499) are associated with the risk of coronary artery diseaseMol Med Rep1423282342201610.3892/mmr.2016.549527430349 AgiannitopoulosKSamaraPPapadopoulouMEfthymiadouAPapadopoulouETsaousisGNMertzanosGBabalisDLamnissouKmiRNA polymorphisms and risk of premature coronary artery diseaseHellenic J Cardiol62278284202110.1016/j.hjc.2020.01.00532092393 BuraczynskaMZukowskiPWacinskiPKsiazekKZaluskaWPolymorphism in microRNA-196a2 contributes to the risk of cardiovascular disease in type 2 diabetes patientsJ Diabetes Complications28617620201410.1016/j.jdiacomp.2014.05.00624972764 YuanSCarterPBruzeliusMVithayathilMKarSMasonAMLinABurgessSLarssonSCEffects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization studyEBioMedicine59102956202010.1016/j.ebiom.2020.10295632805626 TianJAnXNiuLRole of microRNAs in cardiac development and diseaseExp Ther Med1338201710.3892/etm.2016.393228123459 LiXYChenKLvZTAPRISMA-compliant systematic review and meta-analysis determining the association of miRNA polymorphisms and risk of congenital heart diseaseMedicine (Baltimore)98e17653201910.1097/MD.000000000001765331702616 DingYSunXShanPFMicroRNAs and cardiovascular disease in diabetes mellitusBiomed Res Int20174080364201710.1155/2017/408036428299324 TijsenAJCreemersEEMoerlandPDde WindtLJvan der WalACKokWEPintoYMMiR423-5p as a circulating biomarker for heart failureCirc Res10610351039201010.1161/CIRCRESAHA.110.21829720185794 JinCLiZZhengXShenKChaoJDongYHuangQYinQDengYZhuWDevelopment and validation of T-ARMS-PCR to detect CYP2C19*17 alleleJ Clin Lab Anal34e23005202010.1002/jcla.2300531441095

Detection of GCK rs 1799884 G>A gene polymorphism by T-ARMS-PCR in T2DM patients. Lane M, marker 100-bp DNA ladder; lanes P3, P4, P8, and P10, heterozygous patients G/A; lanes, P2, P6, P7, homozygous patients GG allele; lanes, P1, P5, P9, homozygous patients AA allele. GCK, glucokinase; T2DM, type 2 diabetes mellitus; T-ARMS-PCR, tetra primer-amplification refractory mutation system-based polymerase chain reaction.

Detection of MIR-196A-2 rs11614913 C>T gene polymorphism by T-ARMS-PCR in T2DM patients. Lane M, marker 100-bp DNA ladder; lanes P1, P2, P4, P8, P12, heterozygous patients; lanes P3, P5, homozygous TT patients; lanes P6, P7, P9, P10, P11, homozygous CC patients. T2DM, type 2 diabetes mellitus; T-ARMS-PCR, tetra primer-amplification refractory mutation system-based polymerase chain reaction.

Primer sequences of GCK rs1799884 G>A, MIR-196A-2 rs11614913 C>T and MIR-423 rs6505162 C>A genes.

A, ARMS primer sequences of GCK rs1799884 G>A
Gene Amplicon size Temperature
GCK OF 5′-GCTTTCTCTCCTGGTTGTGTTGAG-3′ 390 bp 59°C
GCK OR 5′-GGTCACTGTAGTGACAAGGCGA-3′
GCK IF-C 5′-CCTGCCAGGGCTTACTGGGC-3′ 181 bp
GCK IR-A 5′-GACAACCACAGGCCCTCTCAGTAA-3′ 252 bp
B, ARMS primer sequences of miR-196a-2 rs11614913 C>T
Gene Amplicon size Temperature
MIR-196A-2 OF 5-ACCCCCTTCCCTTCTCCTCCAGATAGAT-3 297 bp 61°C
MIR-196A-2 OR 5-AAAGCAGGGTTCTCCAGACTTGTTCTGC-3
MIR-196A-2 IF (T allele) 5-AGTTTTGAACTCGGCAACAAGAAACGGT-3 199 bp
MIR-196A-2 IR (C allele) 5-GACGAAAACCGACTGATGTAACTCCGG-3 153 bp
C, ARMS primer sequences of miR-423 rs6505162 C>A genes
Gene Amplicon size Temperature
MIR-423 OF 5′-TTTTCCCGGATGGAAGCCCGAAGTTTGA-3′ 336 bp 62°C
MIR-423 OR 5′-TTTTGCGGCAACGTATACCCCAATTTCC-3′
MIR-423 IF (T allele): 5′-TGAGGCCCCTCAGTCTTGCTTCCCAA-3′ 228 bp
MIR-423 IR (C allele) 5′-CAAGCGGGGAGAAACTCAAGCGCGAGG-3′ 160 bp

OF, outer forward; OR, outer reverse; IF, inner forward; IR, inner reverse. GCK, glucokinase.

Demographic features and baseline characteristics of the T2DM patients and controls.

T2DM group Control group
Subject characteristics n % n %
Sex distribution
  Males 61 55.45 65 59.09
  Females 49 44.55 45 40.91
Age distribution (years)
  Age ≤40 20 18.18 23 20.91
  Age >40 23 81.82 87 79.09
Fasting blood glucose (mg/dl)
  Glucose ≤110 28 25.45 96 87.27
  Glucose >110 82 74.55 14a 12.73
Association with RBG (mg/dl)
  RBG ≤200 56 50.91 110 100
  RBG >200 54 49.09 0 0
Total cholesterol (mg/dl)
  Cholesterol ≤200 60 54.55 104 94.55
  Cholesterol >200 50 45.46 6b 05.45
HDL-C (mg/dl)
  HDL-C ≤55 82 74.55 110 100
  HDL-C >55 28 25.45 0 0
LDL-C (mg/dl)
  LDL ≤100 30c 28.57 107 97.27
  LDL >100 75c 71.43 3d 02.73
TG (mg/dl)
  TG ≤150 46 41.82 110 100
  TG >150 64 58.18 0 0
HbA1c
  HbA1c ≤6% 30 27.27 110 0
  HbA1c >6% 80 72.73 0 0
Creatinine (mg/dl)
  Creatinine ≤1.35 83 75.45 110 100
  Creatinine >1.35 27 24.55 0 0

14 subjects in the control group had fasting glucose in the range of 112–115 mg/dl.

6 subjects in the control group had total cholesterol in the range of 204–226.

The LDL-cholesterol values were available in 105 patients only.

3 controls had LDL-cholesterol in the range of 102–109. T2DM, type 2 diabetes mellitus; RBG, random blood glucose; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triacylglycerol; HbA1c, glycated hemoglobin.

Statistical comparisons of GCK (rs1799884 G>A) genotypes in the T2DM patients and controls.

Subjects N GG (%) GA (%) AA (%) χ2 Df G A P-value
T2DM patients 110 26 (23.7) 43 (39) 41 (37.3) 8.4 2 0.43 0.57 0.0150a
Controls 107 30 (28) 56 (52.33) 21 (19.62) 0.54 0.46

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus; GCK, glucokinase.

Statistical comparisons between T2DM patients and controls for GCK (rs1799884 G>A) genotypes using multivariate analysis.

Mode of inheritance Controls (N=107) Patients (N=110) OR (95% CI) RR (95% CI) P-value
Co-dominant
  GCK-GG 30 26 (ref.) (ref.)
  GCK-GA 56 43 0.86 (0.46 to 1.71) 0.94 (0.71 to 1.27) 0.7100
  GCK-AA 21 41 2.25 (1.07 to 4.74) 1.58 (1.03 to 2.42) 0.0320a
Dominant
  GCK-GG 30 26 (ref.) (ref.)
  GCK-(GA+AA) 77 84 1.25 (0.68 to 2.32) 1.12 (0.84 to 1.50) 0.4500
Recessive
  GCK (GG+GA) 86 69 (ref.) (ref.)
  GCK-AA 21 41 2.43 (1.32 to 4.49) 1.63 (1.13 to 2.38) 0.0045a
Allele
  GCK-G 116 95 (ref.) (ref.)
  GCK-A 98 125 1.55 (1.07 to 2.27) 1.25 (1.03 to 1.52) 0.0210a

P<0.05 (statistically significant). Only 107 control samples displayed sharp bands in the gel electrophoresis. T2DM, type 2 diabetes mellitus; GCK, glucokinase; OR, odds ratio; RR, risk ratio; CI, confidence interval.

Statistical comparisons of the clinical features of the T2DM patients with GCK rs1799884 G>A genotypes.

Subject charactetistics N=110 GG GA AA χ2 df P-value
Association with sex
  Males 61 10 40 11 11.8 2 0.0027b
  Females 49 20 16 13
Association with age (years)
  Age ≤40 20 10 6 4 2.12 2 0.3400
  Age >40 90 28 44 18
Fasting glucose (mg/dl)
  Glucose ≤110 28 13 6 9 14.52 2 0.0007b
  Glucose >110 82 20 50 12
Association with RBG (mg/dl)
  RBG ≤200 35 20 10 05 22.0 2 0.0001b
  RBG >200 72 10 46 16
Association with total cholesterol (mg/dl)
  Cholesterol ≤200 60 22 32 06 9.82 2 0.0070b
  Cholesterol >200 50 10 24 16
Association with HDL-C (mg/dl)
  HDL-C ≤55 82 10 50 22 28.8 2 0.0001b
  HDL-C >55 28 09 14 05
Association with LDL-C (mg/dl)
  LDL-C ≤100 30a 10 8 12 3.65 2 0.1600
  LDL-C >100 75a 20 45 10
Association with TG (mg/dl)
  TG ≤150 46 10 28 08 14.2 2 0.0008b
  TG >150 64 10 42 12
Association with HBA1c %
  HBA1c ≤6 30 16 06 08 13 2 0.0013b
  HBA1c >6 80 20 50 10
Association with creatinine (mg/dl)
  Creatinine ≤1.35 83 18 49 16 4.35 2 0.1100
  Creatinine >1.35 27 12 07 08

The LDL-cholesterol values were available in 105 patients only.

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus; GCK, glucokinase; RBG, random blood glucose; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triacylglycerol; HbA1c, glycated hemoglobin.

Distribution of MIR-196A-2 rs11614913 C>T SNP genotypes in T2DM patients and controls.

Subjects N CC (%) CT (%) TT (%) Df χ2 C T P-value
Patients 100a 51 (51) 43 (43) 6 (6) 2 7.84 0.73 0.27 0.0190b
Controls 100a 70 (70) 25 (25) 5 (5) 0.85 0.15

Only 100 T2DM patient and control samples gave sharp bands in the gel electrophoresis for MIR-196A-2 rs11614913 C>T genotyping.

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus.

Statistical comparisons between T2DM patients and controls forMIR-196A-2 rs11614913 C>T genotypes using multivariate analysisa.

Genotypes Healthy controls T2DM cases OR (95% CI) RR P-value
Codominant (N=100)b (N=100)b
  MIR-196A-2-CC 70 51 1 (ref.) 1 (ref.)
  MIR-196A-2-CT 25 43 2.36 (1.28 to 4.35) 1.57 (1.11 to 2.23) 0.0059c
  MIR-196A-2-TT 05 06 1.64 (0.48 to 5.69) 1.27 (0.65 to 2.47) 0.4300
Dominant
  MIR-196A-2-CC 70 51 1 (ref.) 1 (ref.)
  miR-196-CT+TT) 30 49 2.24 (1.25 to 4.01) 1.52 (1.11 to 2.09) 0.0060c
Recessive
  MIR-196A-2-(CC+CT) 95 98 1 (ref.) 1 (ref.)
  MIR-196A-2-TT 05 06 1.16 (0.34 to 3.94) 1.08 (0.56 to 2.10) 0.8000
Allele
  MIR-196A-2-C allele 165 149 1 (ref.) 1 (ref.)
  MIR-196A-2-T allele 35 55 1.74 (1.08 to 2.81) 1.35 (1.02 to 1.78) 0.0230
Over-dominant
  MIR-196A-2-CC+TT 75 57 1 (ref.) 1 (ref.)
  MIR-196A-2-CT 25 43 2.26 (1.24 to 4.13) 1.54 (1.09 to 2.18) 0.0070c

Multivariate analyses was calculated by using MedCalc's software/SPSS 16.0 https://www.medcalc.org/calc/odds_ratio.php.

Only 100 T2DM patient and control samples gave sharp bands in the gel electrophoresis for MIR-196A-2 rs11614913 C>T genotyping.

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus; OR, odds ratio; RR, risk ratio; CI, confidence interval.

Association of MIR-196A-2 rs11614913 C>T SNP genotypes with the T2DM patient characteristics.

Subject characteristics N=100 CC CT TT χ2 df P-value
Association with sex
  Males 61 30 27 04 0.24 2 0.8800
  Females 39 21 16 02
Association with age (years)
  Age ≤40 18 8 8 2 2.4 2 0.3000
  Age >40 82 40 36 6
Fasting glucose (mg/dl)
  Glucose ≤110 21 13 6 02 2.6 2 0.2900
  Glucose >110 79 38 37 04
Association with RBG (mg/dl)
  RBG ≤200 52 22 23 07 10.55 2 0.0050a
  RBG >200 48 26 15 07
Association with total cholesterol (mg/dl)
  Cholesterol ≤200 57 19 34 4 19.89 02 0.0002a
  Cholesterol >200 43 32 09 02
Association with HDL-C (mg/dl)
  HDL-C ≤55 71 16 13 02 03 2 0.9800
  HDL-C >55 29 35 30 04
Association with LDL-C (mg/dl)
  LDL ≤100 28 21 05 02 10.11 2 0.0060a
  LDL >100 72 30 38 04
Association with TG (mg/dl)
  TG ≤150 37 24 10 03 6.13 2 0.0470a
  TG >150 63 27 33 03
Association with HBA1c %
  HBA1c ≤6 24 10 10 4 6.54 2 0.0380
  HBA1c >6 76 41 33 2
Association with creatinine (mg/dl)
  Creatinine ≤1.35 76 29 33 14 4.11 2 0.1200
  Creatinine >1.35 24 22 10 02

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus; RBG, random blood glucose; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triacylglycerol; HbA1c, glycated hemoglobin.

Association of MIR-423 rs6505162 C>A gene variation in T2DM patients and controls.

Subjects N CC (%) CA (%) AA (%) Df χ2 C A P-value
Patients 100 23 (23) 67 (67) 10 (10) 2 7.44 0.62 0.38 0.0240a
Controls 100 35 (35) 48 (48) 17 (17) 0.59 0.41

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus.

Multivariate analysis to estimate the association between MIR-423 rs6505162 C>A gene genotypes and risk to T2DM.

Genotypes Healthy controls (N=100) T2DM patients (N=100) OR (95% CI) RR P-value
Codominant
  MIR-423-CC 35 23 1 (ref.) 1 (ref.)
  MIR-423-CA 48 67 2.12 (1.12 to 4.04) 1.44 (1.07 to 1.95) 0.0210a
  MIR-423-AA 17 10 0.89 (0.35 to 2.29) 0.95 (0.67 to 1.37) 0.8100
Dominant
  MIR-423-CC 35 23 1 (ref.) 1 (ref.)
  MIR-423-(CA+AA) 65 77 1.80 (0.97 to 3.35) 1.31 (1.01 to 1.74) 0.6300
Recessive
  MIR-423-(CC+CA) 83 90 1 (ref.) 1 (ref.)
  MIR-423-AA 17 10 0.54 (0.24 to 1.25) 0.76 (0.55 to 1.06) 0.1500
Allele
  MIR-423-C 118 113 1 (ref.) 1 (ref.)
  MIR-423-A 82 87 1.10 (0.75 to 1.65) 1.05 (0.86 to 1.29) 0.6100
Over-dominant
  MIR-423-CC+AA 52 33 1 (ref.) 1 (ref.)
  MIR-423-A 17 10 0.92 (0.38 to 2.27) 0.97 (0.69 to 1.36) 0.8600

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus; OR, Odds ratio; RR, risk ratio; CI, confidence interval.

Association of MIR-423 rs6505162 C>A with the T2DM patient characteristics.

Subject characteristics N=100 CC CA AA χ2 df P-value
Association with sex
  Males 61 8 47 06 1.6 2 0.4400
  Females 39 9 24 06
Association with age (years)
  Age ≤40 18 7 7 4 18.66 2 0.0001a
  Age >40 82 14 52 14
Fasting glucose (mg/dl)
  Glucose ≤110 21 9 7 5 14.12 2 0.0009a
  Glucose >110 79 14 60 5
Association with RBG (mg/dl)
  RBG ≤200 52 10 39 3 7.23 2 0.0260a
  RBG >200 48 12 30 6
Association with total cholesterol (mg/dl)
  Cholesterol ≤200 57 7 40 5 9.9 2 0.0060a
  Cholesterol >200 43 11 27 5
Association with HDL-C (mg/dl)
  HDL-C ≤55 71 21 44 6 0.66 2 0.7100
  HDL-C >55 29 07 17 5
Association with LDL-C (mg/dl)
  LDL ≤100 28 9 12 7 13.5 2 0.0001a
  LDL >100 72 14 55 3
Association with TG (mg/dl)
  TG ≤150 37 15 17 5 12.47 2 0.0020a
  TG >150 63 8 50 5
Association with HBA1c %
  HBA1c ≤6 24 8 11 5 7.28 2 0.0260a
  HBA1c >6 76 15 56 5
Association with creatinine (mg/dl)
  Creatinine ≤1.35 76 18 44 14 4.56 2 0.1020
  Creatinine >1.35 24 5 16 3

P<0.05 (statistically significant). T2DM, type 2 diabetes mellitus; RBG, random blood glucose; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triacylglycerol; HbA1c, glycated hemoglobin.